Adversarial verification with population-grade epidemiology built in.
Oncology is a $200B+ global category moving through its most consequential therapeutic reset since the original chemotherapy era. The immuno-oncology, antibody-drug conjugate, CAR-T, and cell-and-gene-therapy frontier is repricing the entire portfolio between earnings calls. Reimbursement decisions, AdComm calendar items, and label expansions in flight through 2025–2026 will determine the next decade of oncology run-rate. AimwellBio layers NCI SEER population epidemiology — incidence, survival, mortality, and prevalence — directly on top of corporate, regulatory, and clinical signals. Standard commercial intelligence does not carry this dimension. Most biopharma coverage stops at the pipeline; SEER tells you who the patients are and where they are.
Adversarial verification is the cost of being early.
Checkpoint inhibitors, antibody-drug conjugates, CAR-T, and bispecifics are reshaping the $200B+ oncology run-rate simultaneously. Reimbursement decisions and label expansions in flight through 2025–2026 will determine which manufacturers capture the next cycle of oncology spend. AimwellBio tracks every payer revision, AdComm calendar item, and indication-expansion filing against the companies under your coverage.
AimwellBio integrates NCI SEER Cancer Stat Facts directly into the oncology signal pool: incidence trends, 5-year relative survival, mortality, and lifetime risk across 30 cancer sites. Standard commercial intelligence does not carry this dimension — most pipeline coverage stops at the drug and the company. It is the proof that AimwellBio's intelligence layer extends from corporate filings to population outcomes — the ground truth against which every reimbursement, label, and procurement decision will ultimately be measured.
Every oncology signal carries provenance, source method, and confidence. SEER is public NCI data. ClinicalTrials.gov is public NIH data. SEC filings are public regulator data. AimwellBio verifies, it does not generate. There is no hallucination tolerance for ministry-grade procurement, an investment-committee memo, or a medical-affairs brief delivered to a global oncology KOL.
Every corpus has a shape. The Johari model maps what this corpus knows, what it doesn't yet track, and what's been deliberately obscured in corporate disclosure. Understanding the shape is part of the methodology.
Oncology is repricing inside a regulatory, reimbursement, and sovereign-procurement window most portfolio teams will read about after it closes. The numbers below are the consequences of operating without an adversarial verification layer — and without a population epidemiology floor under it.
global oncology run-rate. Single-indication coverage misses cross-tumor signal cascades — the ADC platform read-across, the checkpoint combo failure, the CAR-T solid-tumor breakthrough.
relative survival for the bottom-quintile cancers — pancreatic, esophageal, liver, lung — remains below 25%. Investors not tracking SEER survival deltas miss the reimbursement trigger when a label moves the curve.
typical lag between an FDA AdComm vote and equity repricing. AdComm dispatch is non-optional for oncology funds. Yesterday’s thesis is not a position.
second chances on a Vision 2030 oncology procurement decision. King Faisal Specialist Hospital and Cleveland Clinic Abu Dhabi anchor the GCC sovereign care layer. The window does not reopen.
Each entity is mapped into AIMN:ATLAS with continuous SEC, ClinicalTrials.gov, PubMed, and NCI SEER coverage. Sovereign-tagged anchors across KSA and the GCC are flagged. Click any name to open its company dossier.
The Surveillance, Epidemiology, and End Results program is the National Cancer Institute’s population-level cancer registry — the ground-truth dataset that defines what is actually happening in incidence, 5-year relative survival, mortality, and lifetime risk across the United States. AimwellBio integrates 30 SEER cancer-site stat facts directly into the oncology signal pool, alongside ClinicalTrials.gov, SEC, and PubMed. The result: every clinical readout, label expansion, and reimbursement decision is read against the population curve it claims to bend.
Free public cancer data, decision-grade intelligence. Premium linked datasets — SEER-Medicare, SEER-CAHPS, and the SEER residual-survival linkage — are reserved for the question that deserves them. The architecture is the same one that supports a sovereign procurement decision: every signal traceable, every recommendation cited, every assumption falsifiable.
Discuss SEER-integrated oncology coverage →New PubMed, ClinicalTrials.gov, and SEC EDGAR entries ingested on each corpus refresh cycle. Source dates, confidence grades, and provenance metadata update with each ingest run.
30 SEER cancer-site stat facts are public NCI registry data. Incidence, 5-year survival, mortality, and lifetime risk. Updated with each NCI SEER release.
1,761 signals and 50 entities reflect the May 2026 indexed corpus. These counts update at the next scheduled corpus rebuild, not in real time.
5-source adversarial PROCEED/DELAY/KILL verdict with confidence score and citation-resolution gate. Member access. ~90s generation on demand.
Analyst estimate from GlobalData 2024 oncology market report. Not recalculated on corpus refresh. Manually updated on major market report releases.
Oncology is structurally a multi-vertical: NSCLC, breast, colorectal, hepatocellular, hematologic, gynecologic, sarcoma, melanoma, and neuroendocrine all route through the same upstream feed. AimwellBio resolves the overlap as a first-class corpus with tumor-type secondary tags applied at filter time — so analysts drill from Oncology → NSCLC → KRAS G12C in one click without losing the broader competitive context.
ADC gross-to-net compression, CAR-T access economics, and bispecific sequencing are repricing simultaneously. AIMN:VERDICT delivers PROCEED/DELAY/KILL with confidence score and SEER survival-delta context before the conviction memo — not after. Every claim source-cited, every conclusion adversarially tested.
Minimal residual disease and circulating tumor DNA literature is arriving faster than any single MSL team can process. AimwellBio structures the frontier into briefable units: KOL movement, SEER-anchored real-world outcomes, and immune-checkpoint long-term data integrated into one structured feed.
KFSHRC, KACST, and MOH formulary decisions on high-cost oncology agents — IO combinations, ADC first-line expansions, CAR-T infrastructure buildout — are tracked through institution-specific procurement timelines. Vision 2030 oncology center capacity expansion mapped across 7 sovereign entities. NDA briefings available.
Pembrolizumab combinations, ADC first-line expansions (T-DXd, EV+P), and CAR-T access pathway disputes are creating payer-tier pressure not visible in approved labels or press releases. AIMN signals formulary committee position, NCCN category shifts, and real-world utilization trends before they crystallize into rebate renegotiations.
SEER tells you who the patients are. SEC tells you what the companies know. ClinicalTrials.gov tells you what's in motion. AimwellBio integrates all three with FDA approval history and PubMed evidence — adversarially validated, source-cited, and hallucination-controlled. One layer that gives an investment committee, a BD team, or a ministry procurement office the same defensible intelligence.
Ministry procurement or NDA briefing? Discuss sovereign deployment →